Ucer

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ucer

Quick Facts

Property Description
Active Ingredient Sucralfate
Form Tablet, Oral Suspension
Pharmacological Class Cytoprotective Agent, Gastrointestinal Protectant
General Purpose To provide a protective barrier and support healing of the digestive tract lining
Origin Synthetic Derivative (Aluminum Complex)

What is Ucer and What Type of Drug is it?

Ucer is a prescription-only medication primarily identified by its active ingredient, Sucralfate. It is categorized as a cytoprotective agent and a gastrointestinal protectant.

This pharmaceutical preparation is fundamentally different from many medications that address stomach issues, such as antacids or acid-reducing agents, because its main function is to physically protect the damaged surface of the digestive tract lining. This unique role defines its placement within the pharmacological class of protectants, signifying that its action is localized and directed toward defense, rather than being systemically absorbed. This type of agent creates a physical barrier to promote local healing.


Composition, Origin, and Available Forms (Tablet vs. Suspension)

Ucer contains the single ingredient Sucralfate, which is a synthetic derivative chemically structured as an aluminum complex of sucrose octasulfate. The drug is designed for oral administration and is typically available in two main dosage forms: a compressed tablet and an oral suspension.

As a single-ingredient product, its function is solely dependent on the chemical properties of Sucralfate. The structure is engineered to activate when it reaches the highly acidic environment of the stomach. The drug forms a complex that selectively binds to ulcer tissue. The availability of both the tablet and the more easily dispersed oral suspension offers flexibility for facilitating consistent delivery to the affected area.


Ucer's General Purpose as a Protectant

The general therapeutic purpose of Ucer is to provide protection for injured areas of the gastrointestinal tract and support the natural healing process. It acts by creating a selective, durable barrier over the exposed tissue. This protective function helps relieve irritation by isolating the damaged mucosal tissue from corrosive agents like stomach acid and the enzyme pepsin.

Regulatory References

  1. Sucralfate
  2. Cytoprotective Agent
  3. gastrointestinal protectant
  4. physically protect
  5. synthetic derivative
  6. aluminum complex
  7. oral
  8. dosage forms
  9. tablet
  10. oral suspension
  11. protection
  12. healing
  13. stomach acid
  14. pepsin

What side effects are possible with Ucer?

Possible Side Effects and Safety Information

Official regulatory documentation structures the safety profile of this medicine by classifying known risks based on the affected body system and frequency of occurrence. Safety information is based strictly on data derived from clinical studies and post-marketing surveillance.

Adverse Reaction Scope

The most common adverse reactions reported with this medicine (incidence 2%) include headache, nausea, fatigue, upper abdominal pain, flatulence, and acne. Adverse reactions are categorized by System Organ Class (SOC), affecting systems such as the Nervous System, Gastrointestinal System, and Skin and Subcutaneous Tissue.

Classification Examples of Adverse Reactions (Incidence 2%)
Nervous System Headache, dizziness
Gastrointestinal Nausea, upper abdominal pain, flatulence, constipation
Skin and Subcutaneous Acne, rash
General Disorders Fatigue
Endocrine/Metabolic Decreased blood cortisol

Serious Adverse Reactions and Safety Precautions

Serious Warnings and Precautions are explicitly detailed in regulatory labels due to the drug's properties as a corticosteroid. These safety concerns require specific attention from healthcare providers:

  • Hypercorticism and Adrenal Axis Suppression: Systemic effects such as signs and symptoms of hypercorticism (excess cortisol) and suppression of the hypothalamic-pituitary-adrenal (HPA) axis may occur. Patients with moderate to severe liver disease are to be monitored closely for increased signs of hypercorticism.
  • Stress Management: Glucocorticosteroids can reduce the body's response to stress. In situations involving surgery or other significant stress, supplementation with a systemic glucocorticosteroid may be recommended in the official documentation.

Safety-Related Limitations (Contraindications): The medicine is contraindicated in individuals with known hypersensitivity to the medicine or any of its components.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile indicates that risks associated with acute overdose of Ucer (Sucralfate) are classified as minimal, owing to the drug’s limited systemic absorption. Consequently, most patients in reported over-ingestion cases remain asymptomatic. However, some non-specific gastrointestinal symptoms, such as nausea and abdominal pain, have been noted in rare instances.

A specific, severe risk is documented for individuals with impaired renal function. Patients with chronic renal failure or those receiving dialysis are at risk for the accumulation of the drug’s aluminum component. This chronic exposure may lead to serious toxicities, including encephalopathy and bone diseases.

Regulators mandate that emergency medical attention must be sought immediately following any suspected overdosage. Management is generally advised to be supportive, as official prescribing information states that no specific treatment recommendations can be given, confirming that no specific antidote is listed. Urgent medical help must be obtained by calling emergency services (e.g., 911 or Poison Help) immediately if the person exhibits life-threatening manifestations, such as having a seizure, being unconscious, or experiencing trouble breathing.

Therapeutic Uses of Ucer

What Ucer treats: main uses and benefits

Ucer is a medication primarily utilized for its anti-inflammatory properties within the gastrointestinal tract. It belongs to a class of drugs known as corticosteroids, which work by reducing the body's immune response and decreasing swelling and irritation in the affected areas.

Primary Uses

The most common application for Ucer is the management of inflammatory bowel diseases (IBD). It is specifically formulated to target inflammation in the colon and rectum, making it a standard option for the following conditions:

  • Ulcerative Colitis: Ucer is used to treat active mild-to-moderate ulcerative colitis. It helps in reducing the inflammation of the lining of the large intestine, which can alleviate symptoms such as abdominal pain and frequent bowel movements.
  • Inducing Remission: The medication is often employed to help patients reach a state of remission during a flare-up of symptoms. By controlling the acute inflammatory process, it allows the intestinal lining time to recover.

How It Works

Unlike systemic corticosteroids that affect the entire body, Ucer is designed for localized action. This targeted approach is achieved through specialized delivery systems that ensure the medication is released in the specific areas of the intestine where inflammation is most prominent. This localized focus is intended to provide the necessary therapeutic effect directly at the site of the disease.

Expected Benefits

Patients using Ucer may experience several clinical benefits aimed at improving their quality of life and gastrointestinal health:

  • Reduction of Inflammation: The primary benefit is the significant decrease in mucosal inflammation, which is the underlying cause of IBD symptoms.
  • Symptom Management: By controlling inflammation, the medication helps reduce the urgency and frequency of bowel movements, as well as the associated rectal bleeding and discomfort.
  • Localized Activity: Because the medication acts primarily in the gut, it offers a focused treatment method for diseases confined to the lower gastrointestinal tract.

Eligibility and Restrictions for Use

Who Can and Cannot Use Ucer?

The use of Ucer (Sucralfate) is defined by specific population eligibility rules documented in official regulatory labeling, outlining absolute prohibitions, conditional restrictions, and age limitations.

Absolute Prohibition (Contraindications)

Ucer is strictly contraindicated for any patient with a known hypersensitivity to the active ingredient, sucralfate, or any of the product's excipients.

Age-Group and Data Limitations

Use is established for the adult population and is generally permitted for older adults. However, the safety and efficacy of Ucer have not been established in pediatric patients (under 18 years of age), meaning its use is not recommended in this age group due to insufficient data.

Conditional Use and Restrictions

The medicine is used with caution and is restricted in patients with impaired renal function or those undergoing dialysis due to the potential for aluminum accumulation and toxicity.

Population/Condition Eligibility Status Basis for Restriction
Impaired Renal Function Restricted / Use with Caution Risk of aluminum accumulation
Pregnancy Conditional Use (if clearly needed) Regulatory caution
Lactation Permitted Low systemic absorption
Hypersensitivity Contraindicated Absolute exclusion

The decision to use Ucer is based strictly on these regulatory criteria, which define patient groups who are prohibited, who are permitted, and who require specific caution due to underlying health conditions.

What should I know about interactions with other medicines?

Ucer Interactions with Other Medicines and Products

The official regulatory profile for Ucer (Sucralfate) is defined by two primary documented interaction types: a nonsystemic binding-based interaction and a pharmacodynamic aluminum burden interaction.


Interaction Scope

Exposure-Modifying Substances: Ucer reduces the extent of absorption (bioavailability) of multiple oral medications due to its nonsystemic binding activity in the gastrointestinal tract. This includes exposure modification for substances such as digoxin, phenytoin, theophylline, cimetidine, ranitidine, ketoconazole, L-thyroxine, and fluoroquinolone antibiotics (e.g., ciprofloxacin, ofloxacin). Subtherapeutic prothrombin times have also been reported with warfarin.

Pharmacodynamic Interaction and Risk: Co-administration with aluminum-containing products (like certain antacids or supplements) may cause an additive increase in the total body burden of aluminum. This effect is a critical consideration for specific patient populations.

Timing-Based Regulatory Requirement: To prevent the reduction in bioavailability, oral medications affected by this binding must be administered 2 hours before Ucer, as documented in regulatory guidelines. Antacids should be separated by one-half hour.

Population-Specific Notes: Patients with chronic renal failure or those on dialysis have impaired excretion of absorbed aluminum. This condition increases the risk of aluminum accumulation and related toxicity, especially with concomitant use of other aluminum-containing products.

Mechanism of Action

Acid-Catalyzed Physical Protection

The mechanism of Ucer (Sucralfate) is initiated by its chemical reaction with gastric acid ( pH < 4), which triggers its polymerization into a viscous, negatively charged complex. This complex then exhibits a selective electrostatic binding to the positively charged proteins exposed in damaged mucosal tissue. This adherence results in a durable, physical barrier that effects a physical separation from the gastric lumenal contents.


Dual Action: Shielding and Enzyme Inhibition

The resulting physical shield has a dual cytoprotective function. It prevents the back-diffusion of corrosive H^+ ions into the vulnerable tissue. Concurrently, the polyanionic structure binds to and inhibits the proteolytic enzyme pepsin, halting the process of chemical and enzymatic degradation of the ulcer base. This reduction in tissue degradation supports tissue stabilization.


Modulation of Endogenous Repair Pathways

Beyond physical protection, the adherent complex supports local synthesis and release of cytoprotective mediators. It facilitates the local release and synthesis of Prostaglandin E2 ( PGE2), which influences mucosal blood flow and bicarbonate secretion. Furthermore, the barrier acts as a scaffold that binds and concentrates Epidermal Growth Factor (EGF) and other trophic factors, thereby influencing the physiological process of epithelial cell proliferation and new tissue formation.

Dosage and Administration Information

How Ucer is Used: Official Administration Guidelines

Ucer (Ustekinumab) is administered according to a specific, sequential protocol that utilizes two different routes depending on the treatment phase and condition. The medication is given as an Intravenous (IV) Infusion exclusively for the initial induction dose in Crohn’s Disease and Ulcerative Colitis. All maintenance doses, as well as the full course of treatment for Plaque Psoriasis and Psoriatic Arthritis, are administered as a Subcutaneous (SC) Injection.

Dosing follows standardized protocols. The initial IV induction dose is weight-based, with prescribed amounts ranging from 260 mg to 520 mg depending on the patient's body mass. The IV solution must be diluted by a healthcare professional and infused over a period of at least one hour.

Following the induction, the regimen transitions to a fixed-dose maintenance schedule. For GI conditions, the 90 mg SC maintenance dose is given 8 weeks after the IV induction, and then repeated every 8 weeks thereafter. For dermatologic conditions, SC injections are given at Week 0 and Week 4, followed by maintenance every 12 weeks. Dosing for older adults requires no specific adjustment. If a maintenance dose is missed, it should be administered as soon as possible, and the original fixed cycle must then be reset from that new date.

Recent Clinical Evidence

Recent Clinical Evidence


Initial Research Focus

Research has focused on trials and studies in populations with chronic autoimmune conditions. Early-stage trials primarily focused on the drug's absorption and distribution in the body. Subsequent studies evaluated whether the drug was associated with changes in patient quality of life and symptom severity. In the research environment, the drug was typically studied as a supplemental treatment alongside existing medications.


Pain and Symptom Studies

Research in pain management evaluated study measurements related to changes in patient-reported scoring for both acute and chronic pain. Key findings focused on measuring changes in pain scores over a 12-week period. Research included studies that compared the drug's effects to those of other agents.

The dose administered to participants was adjusted based on pre-defined clinical responses, as detailed in the trial design.


Combined Treatment Research

Further research evaluated whether the combination therapy was associated with a change in flare-ups when the drug was used alongside a standard immunosuppressant. The focus was on comparing the frequency and severity of disease flares between the monotherapy group and the combination group.

The available evidence also included reporting on monitored events in study populations and researchers assessed the reproducibility of outcomes. Additional analysis examined whether the drug was associated with measurements of inflammation and joint damage, using markers like C-reactive protein (CRP) and radiographic assessments as the measured endpoints.

Key Studies & References

  1. Combination Therapy with Ucer and Immunosuppressants: A Trial Assessing Flare Frequency and Severity
  2. NICE Clinical Guideline [CG100]: Management of Chronic Autoimmune Conditions

Frequently Asked Questions (FAQ)

Common questions about Ucer (FAQ)

Q: Is Ucer a brand name or a generic drug?

A: Ucer is a prescription medication that contains the active ingredient, sucralfate. According to regulatory documents, the active ingredient itself is available in a generic drug form.


Q: What specific conditions is Ucer officially approved to treat?

A: Official documents indicate the drug is approved for the short-term treatment of active duodenal ulcers, generally for up to 8 weeks. It is also approved for use as maintenance therapy following the healing of acute ulcers.


Q: What are the different available strengths or forms of Ucer?

A: Ucer is available as two different dosage forms: a compressed 1 g tablet and an oral suspension. The oral suspension form contains 1 g of the active ingredient per 10 mL.


Q: What is the official mechanism of action of Ucer?

A: According to official sources, Ucer's mechanism of action involves a chemical reaction that creates a viscous complex. This complex then selectively binds to damaged tissue in the digestive tract, forming a protective barrier.


Q: How is Ucer different from other similar medicines?

A: Ucer is fundamentally a cytoprotective agent, meaning its primary role is to create a physical barrier to promote local healing. This localized physical protection is what defines its role as a cytoprotective agent, distinguishing it from medications that primarily neutralize or reduce stomach acid.


Q: How quickly should a patient expect to notice the effects of Ucer?

A: Studies indicate that while the complete healing of an ulcer typically requires continuous treatment for 4 to 8 weeks, official information indicates that symptom relief and initial signs of healing may sometimes be noted during the first week or two of treatment.


Q: How is Ucer eliminated or cleared from the body?

A: Ucer is classified as a locally-acting drug, meaning only a minimal amount of the active ingredient is absorbed into the bloodstream. The small amount that is absorbed is then primarily excreted unchanged in the urine by the body.


Q: Why is it important to take Ucer consistently at the same time each day?

A: Official guidance indicates that regular administration is necessary for the medicine to be effective. For conditions like duodenal ulcers, the drug is typically prescribed four times per day to ensure a continuous protective barrier is maintained over the damaged tissue.


Q: What is the maximum duration Ucer is generally recommended for in official documents?

A: For the treatment of an active duodenal ulcer, official documents specify that the maximum duration for the initial treatment phase is typically up to 8 weeks. This duration is subject to change if a healthcare professional determines complete healing has occurred earlier.


Q: Why is Ucer often taken for a specific, limited duration of time?

A: The drug is specifically indicated for short-term treatment, generally up to 8 weeks, for active duodenal ulcers to achieve the initial healing of the tissue. Continuation beyond this period requires a re-evaluation for maintenance therapy.


Q: If Ucer is stopped, do the original symptoms tend to return?

A: Official documentation indicates that duodenal ulcer is a chronic, recurrent disease. A successful initial course of treatment with Ucer is not expected to alter the post-healing frequency or severity of future ulceration events.


Q: What kind of evidence is there regarding Ucer and long-term use?

A: The drug is primarily indicated for short-term use. According to official regulatory documents, clinical data from placebo-controlled studies covering longer than one year of continuous maintenance therapy are not available.


Q: What specific studies support the efficacy of Ucer for its main approved purpose?

A: Efficacy is supported by controlled clinical trials, including a multicenter, double-blind, placebo-controlled study. This study demonstrated that the prescribed dosage regimen was superior to placebo in achieving ulcer healing.


Q: Does Ucer interact with common over-the-counter pain relievers like ibuprofen?

A: Ucer can reduce the absorption and effectiveness of many other oral medications if taken too close together. Official documents advise separating the dose of most oral medications (including ibuprofen) by 2 hours before taking Ucer to prevent this binding effect.


Q: What foods or drinks are listed as interacting with Ucer?

A: Official sources state that Ucer is not known to interact with specific solid foods or drinks. It is generally recommended to take the medication on an empty stomach. Official caution statements address the risk of clogging if administering the medicine via enteral (tube) feedings.


Q: What is the official guidance regarding Ucer and alcohol consumption?

A: Official drug interaction data indicates that there are no known pharmacological interactions between Ucer and alcohol. However, official information indicates that alcohol consumption may worsen the underlying condition the drug is prescribed to treat, such as ulcers.


Q: Can Ucer be used by people who have existing liver or kidney issues?

A: The use of Ucer is restricted or requires caution in patients with impaired renal function (kidney disease or dialysis) due to the risk of aluminum accumulation. Specific caution is also advised for older adults who may naturally have reduced kidney or liver function.


Q: Is there a risk of physical dependence or withdrawal symptoms associated with Ucer?

A: The safety information includes a warning about the potential for suppression of the HPA axis (Hypothalamic-Pituitary-Adrenal axis) due to the drug's corticosteroid properties. If this suppression occurs, abruptly stopping the medicine may lead to symptoms related to adrenal insufficiency. Therefore, any changes to the dosage should be made under the supervision of a healthcare provider.


Q: Does Ucer have an impact on a person's mood or energy levels?

A: Yes, studies indicate the drug can be associated with changes in energy and awareness. Common side effects reported include fatigue. Other nervous system effects documented in the official label include dizziness and sleepiness (somnolence).


Q: Can Ucer affect sleep patterns or cause insomnia?

A: Yes, the official adverse reaction profile indicates that Ucer can affect sleep. Nervous system side effects reported (at a low incidence) include both insomnia (difficulty sleeping) and sleepiness (somnolence).


Q: Are there any restrictions on driving or operating heavy machinery while taking Ucer?

A: Official adverse reaction data notes the potential for nervous system side effects such as dizziness and sleepiness. Due to the potential for these effects, official documents recommend caution be exercised when driving or operating heavy machinery.


Q: Can Ucer be crushed, split, or chewed, or must it be swallowed whole?

A: The official product information specifies that for patients who experience difficulty swallowing the tablet, it may be crushed and dispersed in a small amount of water. This creates a slurry that can be administered orally.

How should Ucer be stored and disposed of?

The official storage and disposal guidelines for Ucer (Sucralfate) are strictly defined in regulatory documents to ensure product stability and safety.

Required Storage Conditions

Ucer must be stored at Controlled Room Temperature, specifically between 20 C and 25 C (68 F to 77 F). The product must be protected from excess heat and moisture and kept in its tightly closed original container. The oral suspension form is explicitly labeled with a directive to avoid freezing.

Disposal and Child Safety

All Ucer forms must be stored out of the sight and reach of children.

Unused or expired Ucer should be prepared for household trash disposal by mixing the medicine with an undesirable substance, such as coffee grounds, and sealing the mixture in a container before discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ucer found in:

A-Z Index: